SK Bioscience announced on the 29th that it has applied for an item permit for the COVID-19 vaccine candidate GBP510. SK Bioscience predicted that it will be able to commercialize it in the second half of the year after obtaining approval from the MFDS.

The name of the vaccine applied through item approval was SKYCovione Multi Injection. If the MFDS approves the item license, SKYCovione will be the first COVID-19 vaccine in Korea.

SKYCovione's item approval is carried out through a rapid approval process for official item approval, not EUA. If approval is completed, it is expected to be commercialized during the second half of the year. In March, SK Bioscience signed a domestic s